{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"The trial was terminated early by the Sponsor based on a strategic decision and not a safety related decision. At the time of trial termination, 14 patients had received BI-1206. No patients received rituximab. As a result of the early termination Part B of the trial did not open."},"pointOfContact":{"email":"regulatory@cancer.org.uk","organization":"Cancer Research UK Centre for Drug Development","phone":"+44 203 4696878","title":"Regulatory Affairs Manager"}}